CSL Biotherapies Obtains FDA Licensure for Use of Its Thimerosal-Free Pandemic Influenza A (H1N1) 2009 Monovalent Vaccine in Children

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--CSL Biotherapies, a subsidiary of CSL Limited (ASX: CSL), one of the world’s leading manufacturers of influenza vaccine, announced that the U.S. Food and Drug Administration (FDA) has approved the company’s application for accelerated approval of its seasonal flu vaccine, Afluria® (Influenza Virus Vaccine) for use in the pediatric population aged 6 months and older. This approval also included labeling for CSL Biotherapies’ Influenza A (H1N1) 2009 Monovalent Vaccine which is an inactivated influenza virus vaccine now indicated for active immunization of persons ages 6 months and older against influenza disease caused by pandemic (H1N1) 2009 virus. This indication is based on the immune response elicited by the seasonal trivalent Influenza Virus Vaccines manufactured by CSL (Afluria®). CSL’s Influenza A (H1N1) 2009 monovalent vaccine and Afluria are manufactured by the same process. There have been no controlled clinical studies demonstrating a decrease in influenza disease after vaccination with Afluria.

Back to news